logo-loader
Avalon GloboCare Corp

Avalon GloboCare expects to be added to Russell 3000 Index

The Russell 3000 Index is a market-capitalization-weighted equity index that gives investors exposure to the entire US stock market

markets
The New Jersey-based biotech should be added to the massive index after the markets close on June 28

Avalon GloboCare Corp (NASDAQ:AVCO), a developer of cell-based technologies and therapeutics, announced Tuesday that it expects to be added to the Russell 3000 Index.

The Freehold, New Jersey-based company said it should be added to the massive index after the markets close on June 28.

The Russell 3000 Index is a market-capitalization-weighted equity index that gives investors exposure to the entire US stock market. The index tracks the performance of the 3,000 largest US-traded stocks, which represent about 98% of all US incorporated equity securities. 

READ: Avalon GloboCare's stock soars after positive study on first saliva-based biomarker as a diagnostic for oral cancer

"We look forward to our inclusion in the Russell 3000 Index, which we believe reflects our continued growth and the progress we are making at Avalon," said CEO Dr David Jin. "Inclusion in the Russell 3000 Index is expected to benefit our company and shareholders by elevating our exposure within the global investment community."

Avalon is currently in the Russell Microcap Index, a capitalization-weighted index of almost 1,550 small-cap and micro-cap stocks, and will remain on that index for one year.

The company specializes in developing cell-based technologies but is also involved in the management of stem cell banks and clinical laboratories. It also develops proprietary diagnostic and therapeutic products leveraging exosome technology and markets proprietary exosome isolation systems and related products to hospitals.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Avalon GloboCare Corp

Price: 1.6 USD

Market: NASDAQ
Market Cap: $121.05 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avalon GloboCare to produce its first series of clinical-grade exosome...

Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr. David Jin tells Proactive Investors that the biotech company will be producing its first series of clinical grade exosome products, used for skincare and hair growth, by the second half of 2019. Dr. Jin adds that the New Jersey-based company is...

on 6/6/19

2 min read